Month: April 2025
Excerpt from the Press Release: BOSTON and LAUSANNE, Switzerland, March 27, 2025 /PRNewswire/ — Alys Pharmaceuticals, Inc. (“Alys”), an immune-dermatology focused company, today announces that the first patient has been dosed in its Phase IIa trial of ALY-101 in patients suffering from Alopecia Areata (AA), a chronic autoimmune disease with significant unmet medical need that…
Read More
SON-1010 is being studied as a combination therapy with trabectedin (Yondelis®), the first FDA-approved treatment for two types of advanced soft tissue sarcoma after failure of standard chemotherapy, due to the potential for immune mechanism synergies and enhancement of progression-free survival (PFS) The Safety Review Committee found no unexpected toxicities in early dosing of SON-1010…
Read More
Excerpt from the Press Release: SAN DIEGO, March 25, 2025 — Sugar coatings aren’t only for candies; they also help viruses, like the ones that cause COVID-19, hide from their hosts’ immune system. Now, researchers have developed a universal vaccine that targets coronaviruses and the sugars that they use as cover. As demonstrated in animal…
Read More
“The Cancer Therapeutics Innovation Pipeline (CTIP) Program was established to capitalize on Ontario’s expertise in cancer biology and drug discovery. Its aim is to create a pipeline of validated cancer targets and First-in-Class (FiC) or Best-in-Class (BiC), novel, selective lead molecules (small molecules or biologics) that will attract partnerships and/or investment for further preclinical and…
Read More
Excerpt from the Press Release: The last time a new class of antibiotics reached the market was nearly three decades ago — but that could soon change, thanks to a discovery by researchers at McMaster University. A team led by renowned researcher Gerry Wright has identified a strong candidate to challenge even some of the…
Read More- « Previous
- 1
- 2
- 3